

Joan BladÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4580208/publications.pdf>

Version: 2024-02-01

232
papers

18,893
citations

43973

48
h-index

12233

133
g-index

236
all docs

236
docs citations

236
times ranked

11626
citing authors

#	ARTICLE	IF	CITATIONS
1	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. <i>Blood Advances</i> , 2022, 6, 690-703.	2.5	19
2	Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. <i>British Journal of Haematology</i> , 2022, 196, 639-648.	1.2	7
3	Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. <i>British Journal of Haematology</i> , 2022, 196, 649-659.	1.2	6
4	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210884.	1.1	2
5	Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. <i>Haematologica</i> , 2022, 107, 2408-2417.	1.7	19
6	Extramedullary disease in multiple myeloma: a systematic literature review. <i>Blood Cancer Journal</i> , 2022, 12, 45.	2.8	57
7	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. <i>American Journal of Hematology</i> , 2022, , .	2.0	13
8	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 68.	2.8	8
9	Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. <i>Blood Cancer Journal</i> , 2022, 12, 76.	2.8	5
10	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3151-3161.	0.8	40
11	Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. <i>British Journal of Haematology</i> , 2021, 193, 181-187.	1.2	20
12	Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. <i>British Journal of Haematology</i> , 2021, 192, 522-530.	1.2	8
13	Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma. <i>British Journal of Haematology</i> , 2021, 193, 299-306.	1.2	5
14	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 142-154.	5.1	46
15	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 757-767.	0.8	98
16	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
17	Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches. <i>Blood Advances</i> , 2021, 5, 1340-1343.	2.5	7
18	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136

#	ARTICLE	IF	CITATIONS
19	Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy. <i>Cancers</i> , 2021, 13, 2055.	1.7	5
20	Kidney Transplantation in Monoclonal Immunoglobulin Deposition Disease: A Report of 6 Cases. <i>American Journal of Kidney Diseases</i> , 2021, 78, 755-759.	2.1	4
21	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	2.8	14
22	Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8048-8048.	0.8	1
23	Management of patients with difficult-to-treat multiple myeloma. <i>Future Oncology</i> , 2021, 17, 2089-2105.	1.1	1
24	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 785-798.	0.2	22
25	Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 413-420.	0.2	6
26	Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. <i>Blood</i> , 2021, 138, 1901-1905.	0.6	23
27	Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. <i>Annals of Hematology</i> , 2021, 100, 2997-3005.	0.8	2
28	Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. <i>Cancers</i> , 2021, 13, 4924.	1.7	11
29	Why Immunotherapy Fails in Multiple Myeloma. <i>Hemato</i> , 2021, 2, 1-42.	0.2	5
30	Treatment of Patients with Monoclonal Gammopathy of Clinical Significance. <i>Cancers</i> , 2021, 13, 5131.	1.7	8
31	Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. <i>Frontiers in Immunology</i> , 2021, 12, 792609.	2.2	3
32	Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic. <i>Blood</i> , 2021, 138, 2719-2719.	0.6	1
33	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, 192.	2.8	62
34	First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. , 2021, 9, e003783.		17
35	A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. <i>Haematologica</i> , 2020, 105, 201-208.	1.7	48
36	Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 132-141.	6.3	299

#	ARTICLE	IF	CITATIONS
37	Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 6023-6033.	2.5	15
38	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. <i>Cancers</i> , 2020, 12, 3615.	1.7	7
39	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. <i>Leukemia</i> , 2020, 34, 3007-3018.	3.3	26
40	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2020, 190, 346-357.	1.2	17
41	Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 4688-4698.	3.2	30
42	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	2.8	75
43	Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. <i>Advances in Therapy</i> , 2020, 37, 1464-1478.	1.3	8
44	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e370-e380.	2.2	170
45	Supportive Care in AL Amyloidosis. <i>Acta Haematologica</i> , 2020, 143, 335-342.	0.7	11
46	The renal range of the κ/λ sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2020, 21, 111.	0.8	18
47	Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance. <i>Blood</i> , 2020, 136, 5-6.	0.6	2
48	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 135, 2375-2387.	0.6	24
49	Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: Comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8512-8512.	0.8	15
50	HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).. <i>Journal of Clinical Oncology</i> , 2020, 38, e20570-e20570.	0.8	5
51	The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. <i>PLoS ONE</i> , 2020, 15, e0241778.	1.1	5
52	Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3120.	1.0	35
53	Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
54	Six-2 glomerular expression for the prediction of renal outcome in systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 97-98.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. <i>Blood</i> , 2019, 134, 1337-1345.	0.6	148
56	Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2019, 54, 1295-1303.	1.3	6
57	Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. <i>Blood</i> , 2019, 134, 421-431.	0.6	110
58	Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. <i>Blood</i> , 2019, 133, 2664-2668.	0.6	11
59	Pomalidomide&dexamethasone for treatment of soft&tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. <i>European Journal of Haematology</i> , 2019, 102, 389-394.	1.1	21
60	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. <i>Haematologica</i> , 2019, 104, 2358-2360.	1.7	18
61	Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets. <i>Blood</i> , 2019, 134, 4355-4355.	0.6	2
62	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba. <i>Blood</i> , 2019, 134, 1906-1906.	0.6	5
63	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update. <i>Blood</i> , 2019, 134, 1865-1865.	0.6	14
64	Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8005-8005.	0.8	15
65	Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. <i>Leukemia</i> , 2018, 32, 2427-2434.	3.3	8
66	Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project. <i>BMJ Open</i> , 2018, 8, e018850.	0.8	8
67	Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 79-85.	1.4	17
68	Testicular plasmacytoma: unique location or circumstantial presentation?. <i>Leukemia and Lymphoma</i> , 2018, 59, 1769-1771.	0.6	3
69	Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. <i>Leukemia</i> , 2018, 32, 1427-1434.	3.3	48
70	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	3.3	68
71	Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma. <i>Journal of Immunology</i> , 2018, 200, 2581-2591.	0.4	19
72	A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility. <i>Haematologica</i> , 2018, 103, 880-889.	1.7	12

#	ARTICLE	IF	CITATIONS
73	M-protein related disorders: MGCS. Blood, 2018, 132, 1464-1465.	0.6	6
74	The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor. Leukemia, 2018, 32, 2082-2094.	3.3	1
75	A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. Haematologica, 2018, 103, 1518-1526.	1.7	18
76	Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e493-e499.	0.2	20
77	Maintenance Treatment and Survival in Patients With Myeloma. JAMA Oncology, 2018, 4, 1389.	3.4	67
78	Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3245-3245.	0.6	17
79	Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.. Journal of Clinical Oncology, 2018, 36, 8002-8002.	0.8	11
80	Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).. Journal of Clinical Oncology, 2018, 36, e20024-e20024.	0.8	2
81	Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica, 2017, 102, 1099-1104.	1.7	81
82	Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2017, 23, 1269-1275.	2.0	3
83	Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 238-245.	1.4	5
84	Tratamiento del mieloma múltiple asintomático: recomendaciones del Grupo Español de Mieloma. Medicina Clínica, 2017, 148, 517-523.	0.3	3
85	The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in <i>in vitro</i> and <i>in vivo</i> models of multiple myeloma by blockade of Ikaros and MYC signaling. Haematologica, 2017, 102, 1776-1784.	1.7	43
86	Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinaemia. British Journal of Haematology, 2017, 179, 849-851.	1.2	11
87	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. Journal of Clinical Oncology, 2017, 35, 2900-2910.	0.8	248
88	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer, 2016, 122, 2050-2056.	2.0	40
89	Lenalidomide plus dexamethasone versus observation in patients with high-risk smoldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 1127-1136.	5.1	128
90	Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood, 2016, 127, 1896-1906.	0.6	81

#	ARTICLE	IF	CITATIONS
91	Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. <i>Blood</i> , 2016, 127, 420-425.	0.6	51
92	Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. <i>Blood</i> , 2016, 127, 1151-1162.	0.6	68
93	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. <i>Blood</i> , 2016, 127, 3165-3174.	0.6	129
94	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	5.1	1,866
95	Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e71-e77.	0.2	17
96	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. <i>Lancet</i> , The, 2016, 387, 1551-1560.	6.3	724
97	Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 3283-3283.	0.6	2
98	Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2016, 128, 373-373.	0.6	1
99	High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 482-482.	0.6	10
100	BET Bromodomain Blockade Enhances Ikaros Inhibition By Lenalidomide Therapy Providing Additional Activity in In Vitro and In Vivo Models of Multiple Myeloma. <i>Blood</i> , 2016, 128, 308-308.	0.6	0
101	The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival. <i>Blood</i> , 2016, 128, 375-375.	0.6	1
102	Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. <i>Leukemia Research Reports</i> , 2015, 4, 64-69.	0.2	12
103	How I treat relapsed myeloma. <i>Blood</i> , 2015, 125, 1532-1540.	0.6	31
104	A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. <i>British Journal of Haematology</i> , 2015, 170, 804-813.	1.2	38
105	Extramedullary disease in multiple myeloma in the era of novel agents. <i>British Journal of Haematology</i> , 2015, 169, 763-765.	1.2	21
106	Treatment for patients with newly diagnosed multiple myeloma in 2015. <i>Blood Reviews</i> , 2015, 29, 387-403.	2.8	48
107	Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. <i>Blood</i> , 2015, 126, 858-862.	0.6	50
108	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146

#	ARTICLE	IF	CITATIONS
109	Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years. <i>Blood</i> , 2015, 126, 1848-1848.	0.6	2
110	Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials. <i>Blood</i> , 2015, 126, 19-19.	0.6	4
111	Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials. <i>Blood</i> , 2015, 126, 2962-2962.	0.6	1
112	Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hybridization (FISH). <i>Blood</i> , 2015, 126, 4243-4243.	0.6	2
113	Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study. <i>Blood</i> , 2015, 126, 721-721.	0.6	12
114	What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity. <i>Blood</i> , 2015, 126, 725-725.	0.6	1
115	Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA8512-LBA8512.	0.8	4
116	Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA8512-LBA8512.	0.8	17
117	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. <i>Oncotarget</i> , 2015, 6, 1874-1883.	0.8	42
118	The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis. <i>Blood</i> , 2015, 126, 3049-3049.	0.6	0
119	Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 2963-2963.	0.6	0
120	Long-Term Survivors after Stem Cell Transplantation in Multiple Myeloma: Bone Marrow Minimal Residual Disease, PET/CT and Immunological Status. <i>Blood</i> , 2015, 126, 4192-4192.	0.6	0
121	The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients. <i>Blood</i> , 2015, 126, 4181-4181.	0.6	2
122	Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 2955-2955.	0.6	0
123	Extramedullary Myeloma Spread Triggered by Surgical Procedures: An Emerging Entity?. <i>Acta Haematologica</i> , 2014, 132, 36-38.	0.7	12
124	Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma. <i>Annals of Hematology</i> , 2014, 93, 107-111.	0.8	5
125	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
126	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	1.9	90

#	ARTICLE	IF	CITATIONS
127	Issues of front-line therapy for multiple myeloma â€” the standard of care. <i>Leukemia and Lymphoma</i> , 2014, 55, 1959-1961.	0.6	1
128	Response evaluation and monitoring of multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 33-42.	1.0	8
129	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	5.1	695
130	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. <i>Blood</i> , 2014, 123, 3073-3079.	0.6	380
131	Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. <i>Blood</i> , 2014, 124, 2498-2506.	0.6	62
132	GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?. <i>Blood</i> , 2014, 124, 1887-1893.	0.6	95
133	An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 176-176.	0.6	27
134	Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial. <i>Blood</i> , 2014, 124, 3390-3390.	0.6	4
135	Interpretation and Application of the International Myeloma Working Group (IMWG) Criteria: Proposal for Uniform Assessment and Reporting in Clinical Trials Based on the First Study Independent Response Adjudication Committee (IRAC) Experience. <i>Blood</i> , 2014, 124, 3460-3460.	0.6	6
136	Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival. <i>Blood</i> , 2014, 124, 3465-3465.	0.6	6
137	Tumor and Renal Response in Patients with Newly Diagnosed Multiple Myeloma and Renal Failure Treated with Bortezomib and Dexamethasone: Results of a Prospective Phase II Trial from Pethema/GEM. <i>Blood</i> , 2014, 124, 4776-4776.	0.6	1
138	Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CYCLO-LEN-DEX) for Previously Untreated Patients with Light-Chain Amyloidosis (AL). <i>Blood</i> , 2014, 124, 2135-2135.	0.6	0
139	Defining the Differentiation Stage of Multiple Myeloma Plasma Cells: Biological and Clinical Significance. <i>Blood</i> , 2014, 124, 25-25.	0.6	2
140	Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens. <i>Blood</i> , 2014, 124, 2108-2108.	0.6	0
141	Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib. <i>Leukemia Research</i> , 2013, 37, 641-646.	0.4	17
142	Phase III Trial Of Bortezomib, Melphalan, and Prednisone (VMP) Versus Bortezomib, Thalidomide, and Prednisone (VTP) In Elderly Multiple Myeloma (MM) Patients: Update Follow-Up, Patterns Management Of First Relapse/Progression. <i>Blood</i> , 2013, 122, 1973-1973.	0.6	1
143	Comparison Of Sequential Vs Alternating Administration Of Bortezomib, Melphalan and Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) In Elderly Patients With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. <i>Blood</i> , 2013, 122, 403-403.	0.6	4
144	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. <i>Blood</i> , 2013, 122, 767-767.	0.6	56

#	ARTICLE	IF	CITATIONS
145	Prognostic value of deep sequencing method for minimal residual disease (MRD) detection in multiple myeloma.. Journal of Clinical Oncology, 2013, 31, 8511-8511.	0.8	2
146	Lenalidomide (LEN)-melphalan-prednisone induction followed by LEN maintenance (MPR-R) in newly diagnosed multiple myeloma (NDMM) elderly patients (Pts) with moderate renal impairment (RI): MM-015 trial post-hoc analysis.. Journal of Clinical Oncology, 2013, 31, 8544-8544.	0.8	0
147	Characteristics and Outcome Of 66 Patients With Extramedullary Plasmacytomas (EMPs) Included In a Phase III Pethema/GEM Study Of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma (MM). Blood, 2013, 122, 3188-3188.	0.6	1
148	Prognostic Impact Of Serum Heavy/Light Chain Pairs In Patients With MGUS and Smoldering Myeloma: Long-Term Results From a Single Institution. Blood, 2013, 122, 3132-3132.	0.6	0
149	Phenotypic Identification Of Subclones In Multiple Myeloma With Different Genomic Profile, Clonogenic Potential and Drug Sensitivity. Blood, 2013, 122, 531-531.	0.6	0
150	Phenotypic and Genomic Analysis Of Multiple Myeloma (MM) Minimal Residual Disease (MRD) Clonal Plasma Cells (PCs). Blood, 2013, 122, 402-402.	0.6	0
151	Allogeneic Stem-Cell Transplantation In Multiple Myeloma In Real Practice: Long-Term Results From a Single Institution. Blood, 2013, 122, 5524-5524.	0.6	0
152	Prognostic Value Of Deep Sequencing Approach For Minimal Residual Disease (MRD) Detection In Multiple Myeloma Patients. Blood, 2013, 122, 1848-1848.	0.6	0
153	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood, 2012, 120, 1589-1596.	0.6	429
154	Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for lightâ€œchain deposition disease. European Journal of Haematology, 2012, 89, 340-344.	1.1	26
155	Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2012, 30, 8018-8018.	0.8	13
156	Phase II Optimization, Open-Label Clinical Trial of ZalypsisÂ® (PM00104) in Relapsed/Refractory Multiple Myeloma Patients. Blood, 2012, 120, 4041-4041.	0.6	1
157	Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 44-49.	0.2	38
158	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 2011, 117, 4691-4695.	0.6	849
159	Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood, 2011, 118, 4346-4352.	0.6	259
160	Toward deeper response in MM. Blood, 2011, 117, 2986-2987.	0.6	2
161	Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach. Journal of Clinical Oncology, 2011, 29, 3805-3812.	0.8	302
162	Monoclonal gammopathy of undetermined significance: a contraindication for living kidney donation?. CKJ: Clinical Kidney Journal, 2011, 4, 256-257.	1.4	2

#	ARTICLE	IF	CITATIONS
163	Biological and Clinical Significance of CD81 Expression by Clonal Plasma Cells in High-Risk Smoldering and Symptomatic Multiple Myeloma (MM) Patients,. Blood, 2011, 118, 3936-3936.	0.6	1
164	Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005<65years Trials: Clinical Value and Biological Insights,. Blood, 2011, 118, 3938-3938.	0.6	2
165	A Phase III PETHEMA/GEM Randomized Trial of Posttransplant (ASCT) Maintenance in Multiple Myeloma: Superiority of Bortezomib/Thalidomide Compared with Thalidomide and Alfa-2b Interferon,. Blood, 2011, 118, 3962-3962.	0.6	6
166	Influence of Genetic Polymorphisms in CYP1A2, CYP2C19, CYP3A4, GSTP1, MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More). Blood, 2011, 118, 1412-1412.	0.6	0
167	Influence of Lenalidomide Treatment on Immune Effector Cells From High-Risk Smoldering Multiple Myeloma (SMM) Patients,. Blood, 2011, 118, 3944-3944.	0.6	0
168	High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM). Blood, 2011, 118, 630-630.	0.6	0
169	Under Scope of the Current Redefinition Process of Optimal Response in Multiple Myeloma: Assesment of Molecular Response by Fluorescent PCR of Ig Genes Has Similar Applicability and Prognosis Impact to Immunophenotypic Response. (A GEM/PETHEMA study),. Blood, 2011, 118, 3951-3951.	0.6	1
170	Myelodysplasia-Associated Immunophenotypic Abnormalities of Bone Marrow (BM) Cells in Multiple Myeloma (MM): Are They Present At Diagnosis or Can Be Induced by Lenalidomide?. Blood, 2011, 118, 5066-5066.	0.6	1
171	Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood, 2010, 115, 3655-3663.	0.6	113
172	Refining â€œtotal therapyâ€ for myeloma. Blood, 2010, 115, 4152-4153.	0.6	6
173	Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations. Journal of Clinical Oncology, 2010, 28, 690-697.	0.8	101
174	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncology, The, 2010, 11, 934-941.	5.1	427
175	Analysis of Immunophenotypic Response (IR) by Multiparameter Flow Cytometry In 516 Myeloma Patients Included In Three Consecutive Spanish Trials. Blood, 2010, 116, 1910-1910.	0.6	2
176	A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib. Blood, 2010, 116, 307-307.	0.6	19
177	Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination. Blood, 2010, 116, 309-309.	0.6	4
178	Competition Between (Mono)Clonal Plasma Cells and Normal Cells for Potentially Overlapping Bone Marrow Niches Is Associated with a Progressively Altered Cellular Distribution In MGUS Vs. Myeloma. Blood, 2010, 116, 617-617.	0.6	7
179	Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients. Blood, 2010, 116, 2394-2394.	0.6	1
180	Are all myelomas preceded by MGUS?. Blood, 2009, 113, 5370-5370.	0.6	9

#	ARTICLE	IF	CITATIONS
181	Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade)à, Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcadeà, as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial.. Blood, 2009, 114, 130-130.	0.6	24
182	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.. Blood, 2009, 114, 2878-2878.	0.6	18
183	A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years.. Blood, 2009, 114, 3-3.	0.6	13
184	A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.. Blood, 2009, 114, 3852-3852.	0.6	11
185	Efficacy and Safety of Retreatment with Bortezomib in Patients with Multiple Myeloma: Interim Results From RETRIEVE, a Prospective International Phase 2 Study.. Blood, 2009, 114, 3866-3866.	0.6	5
186	Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.. Blood, 2009, 114, 743-743.	0.6	6
187	OPTIMUM Dose of Thalidomide for Relapsed Multiple Myeloma.. Blood, 2009, 114, 959-959.	0.6	1
188	Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin.. Blood, 2009, 114, 109-109.	0.6	7
189	Long Term Significance of Response in Multiple Myeloma After Stem Cell Transplantation.. Blood, 2009, 114, 1811-1811.	0.6	1
190	Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment. Clinical Lymphoma and Myeloma, 2008, 8, 352-355.	1.4	54
191	Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine, 2008, 41, 244-253.	1.4	41
192	SMM: toward better predictors of progression. Blood, 2008, 111, 479-480.	0.6	0
193	Advances in therapy of multiple myeloma. Current Opinion in Oncology, 2008, 20, 697-704.	1.1	29
194	Efficacy and Safety of Re-Treatment with Bortezomib (Velcade®) in Patients with Multiple Myeloma: Results from a Prospective International Phase II Trial. Blood, 2008, 112, 3690-3690.	0.6	10
195	Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2008, 112, 3700-3700.	0.6	6
196	The Effect of Paraprotein Heavy Chain and Free Light Chain Types on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2008, 112, 5190-5190.	0.6	6
197	Effect of Pre and Post-Transplantation Responses on Outcome of Multiple Myeloma Patients: CR and near-CR Should Not Be Considered as Equivalent Prognostic Markers. Results of a PETHEMA/Gem Prospective Study. Blood, 2008, 112, 161-161.	0.6	0
198	The Effect of Bone Marrow Involvement on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Vs Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2008, 112, 5192-5192.	0.6	1

#	ARTICLE	IF	CITATIONS
199	Complications of Multiple Myeloma. Hematology/Oncology Clinics of North America, 2007, 21, 1231-1246.	0.9	71
200	Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside.. Blood, 2007, 110, 1178-1178.	0.6	14
201	Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.. Blood, 2007, 110, 729-729.	0.6	1
202	Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, 2006, 355, 2765-2770.	13.9	97
203	Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. Current Treatment Options in Oncology, 2006, 7, 237-245.	1.3	14
204	Alternating Bortezomib and Dexamethasone as Induction Regimen Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Younger Patients with Multiple Myeloma: Results of a PETHEMA Phase II Trial.. Blood, 2006, 108, 3086-3086.	0.6	3
205	A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone as Primary Therapy for Newly Diagnosed Multiple Myeloma.. Blood, 2006, 108, 795-795.	0.6	17
206	Autologous transplantation in multiple myeloma. Haematologica, 2006, 91, 1157.	1.7	2
207	High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood, 2005, 106, 3755-3759.	0.6	298
208	International Staging System for Multiple Myeloma. Journal of Clinical Oncology, 2005, 23, 3412-3420.	0.8	2,404
209	Renal, hematologic and infectious complications in multiple myeloma. Best Practice and Research in Clinical Haematology, 2005, 18, 635-652.	0.7	61
210	Bortezomib: A valuable new antineoplastic strategy in multiple myeloma. Acta Oncol ³ gica, 2005, 44, 440-448.	0.8	35
211	Thalidomide and dexamethasone in patients with multiple myeloma not undergoing upfront autologous stem cell transplantation. Haematologica, 2005, 90, 1589.	1.7	0
212	Aminoglycoside-associated Severe Renal Failure in Patients with Multiple Myeloma Treated with Thalidomide. Leukemia and Lymphoma, 2004, 45, 1711-1712.	0.6	20
213	Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine, 2004, 26, 145-148.	1.4	34
214	Appropriateness of applying the response criteria for multiple myeloma to Waldenström's macroglobulinemia?. Seminars in Oncology, 2003, 30, 329-331.	0.8	0
215	Transplantation for multiple myeloma: who, when, how often?. Blood, 2003, 102, 3469-3477.	0.6	76
216	Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 2002, 117, 387-389.	1.2	7

#	ARTICLE	IF	CITATIONS
217	Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. British Journal of Haematology, 2001, 113, 422-424.	1.2	73
218	Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. The Hematology Journal, 2001, 2, 272-278.	2.0	50
219	Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease. , 2000, 88, 2142-2148.		17
220	CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH-DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION. British Journal of Haematology, 1998, 102, 1115-1123.	1.2	1,380
221	Pyoderma Gangrenosum Triggered by $\hat{\pm}$ 2b-Interferon in a Patient with Chronic Granulocytic Leukemia. Leukemia and Lymphoma, 1998, 30, 199-202.	0.6	41
222	Risk of relapse and clinicoâ€pathological features in 103 patients with diffuse largeâ€cell lymphoma in complete response after firstâ€line treatment. European Journal of Haematology, 1998, 61, 59-64.	1.1	11
223	CYTOKINE THERAPY IN MULTIPLE MYELOMA*. British Journal of Haematology, 1996, 94, 425-432.	1.2	18
224	Multiple Myeloma Following Essential Thrombocythemia. Leukemia and Lymphoma, 1995, 20, 177-179.	0.6	9
225	An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors. Stem Cells, 1995, 13, 122-125.	1.4	5
226	Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. British Journal of Haematology, 1994, 88, 117-121.	1.2	56
227	Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 1992, 81, 391-394.	1.2	140
228	DEVELOPMENT OF AGGRESSIVE PLASMA CELL LEUKAEMIA UNDER INTERFERON-ALPHA THERAPY. British Journal of Haematology, 1991, 79, 523-525.	1.2	29
229	A new prognostic system for multiple myeloma based on easily available parameters. British Journal of Haematology, 1989, 72, 507-511.	1.2	39
230	IMPACT OF RENAL FUNCTION ON THE MYELOMA STAGING. Scandinavian Journal of Haematology, 1984, 33, 399-400.	0.0	0
231	Cross-resistance to alkylating agents in multiple myeloma. Cancer, 1983, 52, 786-789.	2.0	15
232	Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma. Frontiers in Oncology, 0, 12, .	1.3	3